Immunome CBO Horn Kinney sells $27,300 in stock

Immunome’s NDA for varegacestat was accepted by the FDA for desmoid tumors, supported by Phase 3 RINGSIDE results showing an 84% reduction in the risk of disease progression vs. placebo. Analysts responded positively—H.C. Wainwright reiterated Buy with a $40 price target and Truist raised its target to $37 citing strong efficacy/safety. Separately, CBO Horn Kinney sold 1,092 shares for $27,300 under a Rule 10b5-1 plan, but the stock is up strongly year-over-year and continues to reflect the biotech pipeline momentum.

Analysis

The insider print is noise because it was pre-programmed and option-funded; the real signal is that the market is now paying for regulatory de-risking, not yet for cash generation. In biotech, that usually means the next leg depends on whether the approval path turns into a label with enough commercial breadth to justify the multiple, or whether the story is already discounted by the time the agency steps aside.

The more interesting second-order effect is competitive: this is not an empty category, so any eventual approval likely shifts share rather than creates a brand-new market. That caps the long-run upside unless the profile is meaningfully better on tolerability or convenience, and it makes the stock more sensitive to reimbursement and physician switching than to the headline efficacy slide deck. If launch economics are weaker than the sell-side model, a post-event re-rate lower is more likely than a durable breakout.

Contrarian view: the consensus is probably underestimating sell-the-news risk. The upside case is already extended, so the next catalyst needs to be an approvable label and early adoption data; absent that, the stock can fade even if the regulatory milestone lands. Falsifiers are simple: a CRL, label narrowing, safety drift, or a failure to hold the post-news base around current levels.

Key Decisions for Investors

• Do not chase IMNM here; wait for either a post-event pullback or clearer PDUFA/label visibility before initiating size. If the stock loses its post-acceptance base, assume the market is pricing in too much.
• For event-driven exposure, use a small defined-risk IMNM call spread rather than stock ahead of the next binary catalyst; this limits gap risk if the FDA outcome or label is weaker than expected.
• If already long IMNM, take partial profits into strength and keep the remainder only for the approval window; the trade is about regulatory optionality, not a long-duration fundamental compounder at this valuation.
• Relative-value hedge: long IMNM / short XBI only as a catalyst-specific basket trade into the decision date; exit immediately if the catalyst passes without clear upside follow-through, or if IV remains elevated and the stock stops acting well.